Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Gain Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Gain Therapeutics, Inc.

GANX

Gain Therapeutics, Inc.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a biotechnology company developing small molecule therapeutics targeting protein misfolding and dysfunction across neurodegenerative, lysosomal storage, metabolic, and oncology diseases. Utilizing its Magellan® platform, it identifies allosteric binding sites to create highly specific, brain-penetrant drugs. Its pipeline includes candidates for Parkinson’s disease and other neurodegenerative disorders, focusing on restoring enzyme function and addressing unmet medical needs through innovative, mechanism-based therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Gain Therapeutics, Inc.

1
1
Gain Therapeutics, Inc. Gain Therapeutics Reports $5.6 Million Net Loss in Q1 2026, Seeks Additional Capital

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
Gain Therapeutics, Inc. Gain Therapeutics Reports $20.2 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Gain Therapeutics, Inc. Gain Therapeutics Reports $5.3 Million Net Loss in Q3 2025, Seeks Additional Capital

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Gain Therapeutics, Inc. Gain Therapeutics Reports $5.8 Million Net Loss in Q2 2025, Sees Decrease in Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Gain Therapeutics, Inc. Gain Therapeutics Reports $4.53 Million Net Loss in Q1 2025, Faces Liquidity Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Gain Therapeutics, Inc. Gain Therapeutics Reports $20.4 Million Net Loss for Fiscal Year 2024, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments